Ken Kato, MD, PhD, and Harry H. Yoon, MD, MHS, discussed the recent FDA approval of tislelizumab in the first line for patients with esophageal squamous cell carcinoma.
More than a decade after Merck’s Keytruda and BMS’ Yervoy ushered in the immuno-oncology revolution, the space is at a ...
Amgen, Inc. (“Amgen”) filed three petitions for inter partes review, challenging the validity of all claims in three patents ...
The U.S. Food and Drug Administration (FDA) has approved Fapon Biopharma’s Investigational New Drug (IND) application for ...
A comprehensive study of effective responses as well as resistant responses to a kidney cancer anti-PD-1 therapy found ...
Hosted on MSN1mon
Replimune stock soars on FDA priority review for melanoma treatmentwhich evaluated RP1 in combination with nivolumab in patients with advanced melanoma who had not responded to anti-PD-1 therapies. The FDA's acceptance of the application is particularly ...
Its solution is a licensing deal with Chinese biotech LaNova Medicines for LM-299, which consists of an anti-VEGF antibody joined to the functional parts of a pair of anti-PD-1 antibodies.
Agilent Technologies Inc. (NYSE: A) today announced its PD-L1 IHC 28-8 pharmDx kit has received two new companion diagnostic indications approvals under EU IVDR 1, expanding the eligibility of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback